Johnson & Johnson says FDA grants Fast Track designation to nipocalimab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2025
0mins
Should l Buy JNJ?
FDA Designation: Johnson & Johnson's investigational therapy nipocalimab has received Fast Track designation from the U.S. FDA for treating moderate-to-severe Sjogren's disease, following its earlier Breakthrough Therapy designation.
Lack of Treatments: Currently, there are no approved advanced therapies available for Sjogren's disease, highlighting the significance of this development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 248.560
Low
190.00
Averages
218.50
High
240.00
Current: 248.560
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
J&J CFO: No Significant Financial Impact Expected from Iran Conflict - TD Cowen Conference
Financial Performance Impact: J&J CFO states that the ongoing conflict in Iran does not currently affect the company's financial performance.
Conference Insights: The remarks were made during a recent conference, highlighting the company's resilience amidst geopolitical tensions.
See More
Johnson & Johnson's Nipocalimab Receives FDA Fast Track Designation
- Fast Track Designation: Johnson & Johnson's nipocalimab has received Fast Track designation from the FDA for treating systemic lupus erythematosus, indicating its potential to expedite the drug's market entry for this autoimmune disease.
- Clinical Trial Results: The Phase 2b JASMINE trial demonstrated that nipocalimab significantly reduces lupus disease activity and has the potential for steroid-sparing effects, enhancing its competitive position in the market.
- Ongoing Research: A Phase 3 study named GARDENIA is currently underway to evaluate nipocalimab's efficacy in adults with active systemic lupus erythematosus, further validating its clinical application prospects.
- Stock Performance: JNJ shares closed at $248.56 on Monday, up 0.05%, reflecting market optimism regarding the progress of its new drug development.
See More
Johnson & Johnson Receives FDA Fast Track Designation for Nipocalimab
- FDA Fast Track Designation: Johnson & Johnson's nipocalimab has received Fast Track designation from the FDA, aimed at expediting the development of treatments for systemic lupus erythematosus (SLE), addressing the urgent needs of 3 to 5 million patients worldwide, highlighting the drug's potential in treating serious conditions.
- Clinical Trial Progress: In a Phase 2 study, nipocalimab demonstrated a reduction in lupus disease activity and the potential for steroid-sparing effects, marking its strategic significance in a landscape with limited treatment options.
- Patient Enrollment Initiated: Johnson & Johnson has commenced patient enrollment for the Phase 3 GARDENIA study involving adults with active SLE, further validating nipocalimab's efficacy and potentially providing new treatment options to improve patient quality of life.
- Broad Market Prospects: SLE is a complex chronic autoimmune disease with risks of irreversible organ damage; the successful development of nipocalimab could bring renewed hope to this field, enhancing the company's competitiveness in the biopharmaceutical market.
See More
Johnson & Johnson Receives FDA Fast Track Designation for Nipocalimab in SLE
- FDA Fast Track Designation: Johnson & Johnson's nipocalimab has received FDA Fast Track designation, aimed at expediting treatment for systemic lupus erythematosus (SLE), a disease affecting 3 to 5 million people, highlighting the drug's importance in addressing unmet medical needs.
- Clinical Trial Progress: In a Phase 2 study, nipocalimab demonstrated potential in reducing lupus disease activity, and patient enrollment for the Phase 3 GARDENIA study is currently underway to further validate its efficacy and safety.
- Urgent Market Demand: SLE is a serious chronic autoimmune disease with risks of irreversible organ damage, underscoring the critical need for new treatment options, and the development of nipocalimab could significantly enhance patients' quality of life.
- Innovative Treatment Prospects: As the only FcRn blocker shown to reduce SLE disease activity, the successful development of nipocalimab could provide new treatment options for SLE patients, potentially transforming the treatment landscape in this field.
See More
Dividend Stocks Surge Amid Market Volatility, Outperforming S&P 500
- Dividend Stocks Performance: In 2026, dividend aristocrats are outperforming the broader market, with the ProShares S&P 500 Dividend Aristocrats ETF up 10% year-to-date compared to less than 1% for the S&P 500, reflecting investors' preference for stable income amid market volatility.
- Coca-Cola Dividend Increase: Coca-Cola announced a 4% increase in its quarterly dividend to 53 cents per share in February, marking its 64th consecutive year of dividend growth, and returned $8.8 billion to shareholders last year, demonstrating strong cash flow and market stability.
- NextEra Energy's Growth Plans: NextEra Energy raised its quarterly dividend by 10% to about 62 cents per share and plans for 10% annual dividend growth through 2026, with ambitions to add 30 gigawatts of new generation capacity by 2035, showcasing its commitment to renewable energy.
- Abbott Laboratories' Sustained Growth: Abbott announced a 6.8% dividend increase to 63 cents per share in December, achieving 54 consecutive years of growth, and despite missing fourth-quarter revenue expectations, its dividend growth of over 70% reflects strong profitability and market confidence.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
J&J CFO: No Significant Financial Impact Expected from Iran Conflict - TD Cowen Conference
Financial Performance Impact: J&J CFO states that the ongoing conflict in Iran does not currently affect the company's financial performance.
Conference Insights: The remarks were made during a recent conference, highlighting the company's resilience amidst geopolitical tensions.
See More
Johnson & Johnson's Nipocalimab Receives FDA Fast Track Designation
- Fast Track Designation: Johnson & Johnson's nipocalimab has received Fast Track designation from the FDA for treating systemic lupus erythematosus, indicating its potential to expedite the drug's market entry for this autoimmune disease.
- Clinical Trial Results: The Phase 2b JASMINE trial demonstrated that nipocalimab significantly reduces lupus disease activity and has the potential for steroid-sparing effects, enhancing its competitive position in the market.
- Ongoing Research: A Phase 3 study named GARDENIA is currently underway to evaluate nipocalimab's efficacy in adults with active systemic lupus erythematosus, further validating its clinical application prospects.
- Stock Performance: JNJ shares closed at $248.56 on Monday, up 0.05%, reflecting market optimism regarding the progress of its new drug development.
See More
Johnson & Johnson Receives FDA Fast Track Designation for Nipocalimab
- FDA Fast Track Designation: Johnson & Johnson's nipocalimab has received Fast Track designation from the FDA, aimed at expediting the development of treatments for systemic lupus erythematosus (SLE), addressing the urgent needs of 3 to 5 million patients worldwide, highlighting the drug's potential in treating serious conditions.
- Clinical Trial Progress: In a Phase 2 study, nipocalimab demonstrated a reduction in lupus disease activity and the potential for steroid-sparing effects, marking its strategic significance in a landscape with limited treatment options.
- Patient Enrollment Initiated: Johnson & Johnson has commenced patient enrollment for the Phase 3 GARDENIA study involving adults with active SLE, further validating nipocalimab's efficacy and potentially providing new treatment options to improve patient quality of life.
- Broad Market Prospects: SLE is a complex chronic autoimmune disease with risks of irreversible organ damage; the successful development of nipocalimab could bring renewed hope to this field, enhancing the company's competitiveness in the biopharmaceutical market.
See More
Johnson & Johnson Receives FDA Fast Track Designation for Nipocalimab in SLE
- FDA Fast Track Designation: Johnson & Johnson's nipocalimab has received FDA Fast Track designation, aimed at expediting treatment for systemic lupus erythematosus (SLE), a disease affecting 3 to 5 million people, highlighting the drug's importance in addressing unmet medical needs.
- Clinical Trial Progress: In a Phase 2 study, nipocalimab demonstrated potential in reducing lupus disease activity, and patient enrollment for the Phase 3 GARDENIA study is currently underway to further validate its efficacy and safety.
- Urgent Market Demand: SLE is a serious chronic autoimmune disease with risks of irreversible organ damage, underscoring the critical need for new treatment options, and the development of nipocalimab could significantly enhance patients' quality of life.
- Innovative Treatment Prospects: As the only FcRn blocker shown to reduce SLE disease activity, the successful development of nipocalimab could provide new treatment options for SLE patients, potentially transforming the treatment landscape in this field.
See More
Dividend Stocks Surge Amid Market Volatility, Outperforming S&P 500
- Dividend Stocks Performance: In 2026, dividend aristocrats are outperforming the broader market, with the ProShares S&P 500 Dividend Aristocrats ETF up 10% year-to-date compared to less than 1% for the S&P 500, reflecting investors' preference for stable income amid market volatility.
- Coca-Cola Dividend Increase: Coca-Cola announced a 4% increase in its quarterly dividend to 53 cents per share in February, marking its 64th consecutive year of dividend growth, and returned $8.8 billion to shareholders last year, demonstrating strong cash flow and market stability.
- NextEra Energy's Growth Plans: NextEra Energy raised its quarterly dividend by 10% to about 62 cents per share and plans for 10% annual dividend growth through 2026, with ambitions to add 30 gigawatts of new generation capacity by 2035, showcasing its commitment to renewable energy.
- Abbott Laboratories' Sustained Growth: Abbott announced a 6.8% dividend increase to 63 cents per share in December, achieving 54 consecutive years of growth, and despite missing fourth-quarter revenue expectations, its dividend growth of over 70% reflects strong profitability and market confidence.
See More
